LAUSANNE, Switzerland, June 09, 2023 (GLOBE NEWSWIRE) ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in
This will simplify the design process and allows a near-optimal composite phase change material. Researchers discover a new way to design composite phase change materials that has the ability to store energy as heat.
/PRNewswire/ The global facial rejuvenation products industry size was valued at USD 104.7 billion in 2022 and will exhibit a 6.4% CAGR during the forecast.